Comparison Friction: Experimental Evidence from Medicare Drug Plans
Abstract
Consumers need information to compare alternatives for markets to function efficiently.Recognizing this, public policies often pair competition with easy access to comparative information.The implicit assumption is that comparison friction-the wedge between the availability of comparative information and consumers' use of it-is inconsequential because information is readily available and consumers will access this information and make effective choices.We examine the extent of comparison friction in the market for Medicare Part D prescription drug plans in the United States.In a randomized field experiment, an intervention group received a letter with personalized cost information.That information was readily available for free and widely advertised.However, this additional step-providing the information rather than having consumers actively access it-had an impact.Plan switching was 28 percent in the intervention group, versus 17 percent in the comparison group, and the intervention caused an average decline in predicted consumer cost of about $100 per year among letter recipients-roughly 5 percent of the cost in the comparison group.Our results suggest that comparison friction can be large even when the cost of acquiring information is small, and may be relevant for a wide range of public policies that incorporate consumer choice.
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.